Patrick McGuire was named Chief Accounting Officer of Organogenesis Holdings Inc. As of November 14, 2026, Organogenesis Holdings Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on February 23, 2026, naming 1 appointment (Form 8-K, February 23, 2026).
29 companies changed executives this week, 1 had other signals.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| ONITY GROUP INC. | announced the departure of its Chief Investment Officer | |
| Adicet Bio, Inc. | announced the departure of its Director | |
| MAMMOTH ENERGY SERVICES, INC. | announced the departure of its Chief Operating Officer | |
| CERENOME, INC. | named a new Director | |
| Cohen & Co Inc. | named a new Chief Executive Officer |
Sell to companies like Organogenesis Holdings Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Organogenesis Holdings Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-02-23. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Organogenesis Holdings Inc. files it.
Also on the record for Organogenesis Holdings Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| February 17, 2026 | Stake report, Schedule 13G/A, by Mathew P. Arens | 3.06% of the class | 5%+ stakes | Source |
| February 12, 2026 | Stake report, Schedule 13G/A, by Soleus Capital Master Fund, L.P. | 7.9% of the class | 5%+ stakes | Source |
| November 3, 2025 | Stake report, Schedule 13D/A, by Glenn H. Nussdorf | 9.7% of the class | 5%+ stakes | Source |
| August 14, 2025 | Stake report, Schedule 13G, by Mathew P. Arens | 6.55% of the class | 5%+ stakes | Source |
| November 27, 2024 | Form D, private offering | $130M sold | Form D page | Source |
Selling to them or working with them? See who runs Organogenesis Holdings Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Organogenesis Holdings Inc. and the records around it.
Organogenesis Holdings Inc. elsewhere on the record
- 5%+ stake filings Feb 2026
- Who owns it
Companies that share a holder
- First Light Asset Management, LLC also filed stake reports on 12 other companies: NeuroPace Inc (Sep 2026), Neogenomics, Inc. (Aug 2026), PALVELLA THERAPEUTICS, INC. (Aug 2026)
- Soleus Capital Master Fund, L.P. also filed stake reports on 24 other companies: Beta Bionics, Inc. (Nov 2026), Evolus, Inc (Nov 2026), INSPIRE MEDICAL SYSTEMS, INC. (Nov 2026)
Watch Organogenesis Holdings Inc.
Get an email when Organogenesis Holdings Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Organogenesis Holdings Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Organogenesis Holdings Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Organogenesis Holdings Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
6 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-02-23 | In | Chief Accounting Officer | 8-K, 2026-02-23 |
Who leads Organogenesis Holdings Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Accounting Officer: Patrick McGuire, appointed (filed 2026-02-23).
New leaders reset buying decisions — get the Full Report on Organogenesis Holdings Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Accounting Officer at Organogenesis Holdings Inc., with the record behind each one.
Find candidates like Chief Accounting Officer at Organogenesis Holdings Inc.Every change, in the filing's words
Appointed: Patrick McGuire, Chief Accounting Officer
On February 18, 2026, the board of directors of Organogenesis Holdings Inc. (the "Company") appointed Patrick McGuire, 40, to serve as Chief Accounting Officer and principal accounting officer of the Company, effective immediately.
- Patrick McGuire previously served as the Company's Vice President, Corporate Controller since September 2023.
- Prior to joining the Company, Mr. McGuire was the Corporate Controller at Cynosure, LLC from July 2022 to September 2023 and worked at PricewaterhouseCoopers LLP for over thirteen years in various roles, with an emphasis on pharmaceutical, life sciences and medical device organizations, most recently as a Director from July 2019 to July 2022.
- Mr. McGuire holds a B.A. in Economics and Accounting from the College of the Holy Cross and is a licensed Certified Public Accountant in the state of Massachusetts.
- In connection with Mr. McGuire's appointment as Chief Accounting Officer and principal accounting officer, his annual base salary was increased to $345,000.
- No other changes to Mr. McGuire's existing compensation arrangements were made in connection with his appointment.
Tools for this story
Each opens in a new tab, filled in for Organogenesis Holdings Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.
